A Phase 2 randomized, placebo-controlled proof-of-concept clinical trial in pediatric DMD patients
Latest Information Update: 20 May 2025
At a glance
- Drugs SAT 3247 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 20 May 2025 New trial record
- 12 May 2025 According to a Satellos Bioscience media release, global regulatory filings to obtain approvals to initiate a Ph 2 randomized, placebo-controlled proof-of-concept clinical (POC) trial in pediatric DMD patients expected to be submitted in Q3 2025.